Comparison of different thresholds of PSA density for risk stratification of PI-RADSv2.1 categories on prostate MRI

1ROSSANO GIROMETTI, MD, 2GIANLUCA GIANNARINI, MD, 3VALERIA PANEBIANCO, MD, 1SILVIO MARESCA, MD, 1LORENZO CERESER, MD, 4MARIA DE MARTINO, MD, 5STEFANO PIZZOLITTO, MD, 5MARTINA PECORARO, MD, 5VINCENTINO FICARRA, MD, 1CHIARA ZUIANI, MD and 2CLAUDIO VALOTTO, MD

1Department of Medicine, Institute of Radiology, University of Udine, Santa Maria della Misericordia University Hospital, Udine, Italy
2Urology Unit, Santa Maria della Misericordia University Hospital, Udine, Italy
3Department of Radiological Sciences, Oncology and Pathology, Sapienza University of Rome, Rome, Italy
4Division of Medical Statistic, Department of Medicine, University of Udine, Udine, Italy
5Pathology Unit, Santa Maria della Misericordia University Hospital, Udine, Italy
6Department of Human and Paediatric Pathology “Gaetano Barresi”, Urologic Section, University of Messina, Messina, Italy

Address correspondence to: Prof Rossano Girometti
E-mail: rossano.girometti@uniud.it

Chiara Zuiani and Claudio Valotto have contributed equally to this study and should be considered as senior authors.

INTRODUCTION

Over the last years, prostate magnetic resonance imaging (MRI) has been validated as a tool to minimize the detection of clinically indolent and maximize the detection of clinically significant, prostate cancer compared to conventional transrectal ultrasound-guided systematic biopsy.1–5 Moreover, the high sensitivity and low false-negative rate of prostate MRI account for a potential 30% reduction of unnecessary biopsies in men without clinically significant prostate cancer (csPCA).6 There is intense research on risk-adapted strategies for the proper selection of candidate to prostate biopsy and the reduction of false-negative results.7

OBJECTIVES: To compare the effect of different PSA density (PSAD) thresholds on the accuracy for clinically significant prostate cancer (csPCA) of the Prostate Imaging Reporting And Data System v.2.1 (PI-RADSv2.1).

METHODS: We retrospectively included 123 biopsy-naïve men who underwent multiparametric magnetic resonance imaging (mpMRI) and transperineal mpMRI-targeted and systematic prostate biopsy between April 2019 and October 2020. mpMRI, obtained on a 3.0T magnet with a PI-RADSv2.1-compliant protocol, was read by two radiologists (>1500/>500 mpMRI examinations). csPCA was defined as International Society of Urogenital Pathology grading group ≥2. Receiver operating characteristic analysis was used to calculate per-index lesion sensitivity, specificity, and area under the curve (AUC) of PI-RADSv2.1 categories after adjusting for PSAD ≥0.10, ≥0.15, and ≥0.20 ng/mL ml⁻¹. Per-adjusted category cancer detection rate (CDR) was calculated, and decision analysis performed to compare PSAD-adjusted PI-RADSv2.1 categories as a biopsy trigger.

RESULTS: csPCA prevalence was 43.9%. PSAD-adjustment increased the CDR of PI-RADSv2.1 category 4. Sensitivity/ specificity/AUC were 92.6%/53.6%/0.82 for unadjusted PI-RADS, and 85.2%/72.4%/0.84, 62.9%/85.5%/0.83, and 92.4%/53.6%/0.82 when adjusting PI-RADS categories for a 0.10, 0.15, and 0.20 ng/mL ml⁻¹ PSAD threshold, respectively. Triggering biopsy for PI-RADS four lesions and PSAD ≥0.10 ng/mL ml⁻¹ was the strategy with greatest net benefit at 30 and 40% risk probability (0.307 and 0.271, respectively).

CONCLUSIONS: PI-RADSv2.1 category four with PSAD ≥0.10 ng/mL ml⁻¹ was the biopsy-triggering cut-off with the highest net benefit in the range of expected prevalence for csPCa.

ADVANCES IN KNOWLEDGE: 0.10 ng/mL ml⁻¹ is the PSAD threshold with higher clinical utility in stratifying the risk for prostate cancer of PI-RADSv2.1 categories.
On the other hand, unnecessary biopsy may result from MRI lesions that are associated with a low detection rate of csPCA, such as the Prostate Imaging–Reporting And Data System (PI-RADS) category 3 findings, which harbor csPCA in 25% of cases only.5 Most successful attempts to stratify csPCA risk inherent to category 3 observations have relied on PSA density (PSAD), which has been advocated as a tool to differentiate between PI-RADS 3 lesions requiring biopsy (high PSAD, need to avoid false-negatives) or not (low PSAD, need to avoid false-positives).5 Adjusting PI-RADS categories for PSAD also showed the potential to increase cancer detection rate (CDR) in PI-RADS 1–2 categories, suggesting that PSAD-based adjustments might be of value in different PI-RADS categories.

PI-RADS 4 category is an additional source of false-positives, as suggested by the relatively low CDR found in a study by Tan et al15 (54%) and a systematic review by Barkovich et al11 (48%). Little is known on the effect of PSAD adjustment of category 4 lesions, as they have been usually merged with category 5 ones in previous studies.14 Moreover, while 0.15 ng/ml ml−1 is the most commonly used PSAD cut-off in the radiological literature, different PSAD thresholds and ranges have been proposed to stratify individual patient risk. After pooling the results of five studies on biopsy-naïve patients, Schoots et al16 recently evaluated the effect of adjusting PI-RADS categories with different PSAD thresholds (0.10, 0.15, and 0.20 ng/ml ml−1), showing a progressive increase in false-negatives and decrease in false-positives as the cut-off increased. To our knowledge, only one previous multicenter study by Falagario et al15 compared those thresholds in the same population of roughly 2500 men. On decision analysis, the authors found that performing biopsy for highly suspicious imaging findings (PI-RADS or Likert 4–5 categories), and/or suspicious imaging findings (PI-RADS or Likert 3 category) combined with PSAD > 0.20 ng/mL ml−1 was the strategy achieving the highest net benefit in biopsy-naïve subjects. However, study results have been obtained using mixed interpretation criteria, and in the focused scenario of the Prostate MRI Outcome Database. As far as we know, no previous studies compared PSAD thresholds in the context of more homogeneous and standardized interpretation criteria.

The purpose of our study was to investigate the clinical utility of different thresholds of PSAD in improving the accuracy of PI-RADS categories for detecting csPCA on mpMRI and mpMRI-targeted and systematic biopsy.

METHODS AND MATERIALS

Patients

This study was approved by the Institutional Review Board of the Department of Medicine, University of Udine. A waiver for informed consent acquisition was obtained in view of the retrospective design. By setting April 2019 to October 2020 as the reference period, we performed a computerized search to identify all men who underwent mpMRI at our institution because of persistently increased serum PSA level (≥3 ng ml−1 over at least two repeated samples) and/or suspicious digital rectal examination. In all patients, serum PSA level was obtained ≤1 month before mpMRI. Of 355 resulting subjects, we included 166 biopsy-naïve men who underwent prostate biopsy at our institution ≤3 months from mpMRI because of PI-RADS ≥3 observations, or family history of csPCA regardless of a negative mpMRI result (PI-RADS 1–2). Of note, PSAD was not used to stratify PI-RADS categories in clinical practice. PI-RADS categories were attributed using v.2.1 (PI-RADSv.2.1).

Exclusion criteria were absence of contrast administration due to contraindications (n = 7), poor image quality due to artifacts from air in the rectum (n = 2), and ongoing therapy with 5-alfa reductase inhibitor at the time of mpMRI (n = 21). The latter exclusion criterion was adopted to prevent potential effects of the therapy on diffusion-weighted imaging (DWI) (e.g. reduced conspicuity on DWI images)6,17 and avoid the confounder of calculating PSAD over a prostate gland volume potentially reduced by the effect of therapy.8 We also excluded 13 men in whom mpMRI was not interpreted by the reference readers. The final cohort, thus, included 123 men.

mpMRI protocol

Examinations were performed on a 3.0T magnet (Achieva, Philips) with a 32-channel surface coil after rectal enema and intramuscular administration of 20 mg hyoscine butylbromide as an antispasmodic agent (except when contraindicated). Sequences and acquisition parameters are shown in Supplementary Material 1. Using the vendor software, the apparent diffusion coefficient (ADC) map was built by fitting signal intensity versus all the b-values of the DWI sequence with a maximum b-value of 1000 s/mm². Dynamic contrast-enhanced (DCE) imaging was performed after intravenous administration of 0.1 mmol/Kg gadoteridol (Prohance, Bracco) at an injection rate of 3 ml s−1, using a remote-controlled power injector (Medrad Spectris Solaris EP). Subtraction images were automatically provided for the analysis (pre-contrast acquisition subtracted to each post-contrast acquisition).

Image analysis

Analysis was performed using the mpMRI reports provided during clinical activity by one of two readers, that is, reader 1 (R1) and reader (R2) with an overall mpMRI experience of >1500 examinations and >500 examinations in total, respectively. Both R1 and R2 have been serving as reference radiologists in the prostate multidisciplinary group of our institution (one meeting per week). Readers evaluated mpMRI images on a picture and archive communication system (PACS) workstation (SuiteEstensa, Esaote), using PI-RADSv.2.1 criteria for categorizing image findings and calculating prostate volume (Supplementary Material 1).19 In our institutional practice, mpMRI lesions are marked on the PI-RADSv.2.1 sector map attached to the report, as well directly as on axial T2-weighted and mpMRI images. Given the clinical scenario in which examinations were performed, R1 and R2 were unblinded to indication to mpMRI and clinical information, including PSAD. An independent radiologist with 3 years of experience in prostate imaging (<500 examinations in total) collected all the mpMRI reports and re-assessed the images on the same PACS station in order to identify the index lesion for each examination, defined as the lesion showing the highest PI-RADSv.2.1 category in the
original report. In the case of ≥2 lesions with the same category, the largest one was assumed to represent the index lesion. The examination was categorized as PI-RADSv2.1 if no lesions were reported. Index lesions were assumed to be suspicious for csPCa when categorized as PI-RADSv2.1 ≥3.

Prostate biopsy and standard of reference

Prostate biopsy was performed under local anesthesia via transperineal approach by a single urologist with 2 years of experience using the Apio 300 platform (Toshiba/Canon) with rigid image registration and electromagnetic needle tracking. Targeted biopsy of PI-RADS ≥3 lesions was performed first, deploying a total of 4 cores (two in-target and two peri-target). Subsequent systematic biopsy included the conventional 12-core template. Histological analysis of biopsy samples was the standard of reference. One of three genitourinary pathologists (5–30 years of experience) performed analysis according to International Society of Urological Pathology (ISUP) criteria.20 csPCa was defined as ISUP grading group ≥2 on targeted and/or systematic biopsy.

Statistical analysis

Variables were reported with descriptive statistics, using median and interquartile range (IQR) values and percent proportions with 95% confidence intervals (95% CI). We calculated the CDR of targeted biopsy, defined as the per-patient prevalence of csPCa over PI-RADS ≥3 index lesions, and of targeted plus systematic biopsy, defined as the per-patient prevalence of csPCa in targeted cores and/or systematic cores. CDR was stratified by PI-RADSv2.1 category ≤2, 3, 4, and 5, as well as for three different thresholds of PSAD, namely, ≥0.10, ≥0.15, and ≥0.20 ng/ml ml⁻¹.

By matching the results of mpMRI and biopsy according to the rules shown in Supplementary Material 1, we run receiver operating characteristic (ROC) analysis to assess per-patient sensitivity, specificity, and area under the curve (AUC) of unadjusted and PSAD-adjusted PI-RADSv2.1 categories for csPCa, as shown in Supplementary Material 1. For instance, PI-RADSv2.1 category 3 was divided into 3l (low PSAD) and 3h (high PSAD), depending on whether PSAD exceeded, or not, the established cut-off (e.g., 0.10 ng/ml ml⁻¹). PI-RADSv2.1 and PI-RADSv2.1-adjusted category achieving the highest Youden index was set as the cut-off for maximizing both sensitivity and specificity.21 AUCs obtained at different PSAD thresholds were compared using the DeLong method. Positive-predictive value (PPV) and negative-predictive value (NPV) were calculated as well. Alpha level for statistical significance was set at 0.05.

Finally, we used the decision analysis22 to quantify the clinical utility of different models potentially determining the need for targeted plus systematic biopsy in our series, that is, biopsy for no patients (“treat none” strategy), biopsy for all patients (“treat all” strategy), and biopsy for index observations with the following categories: PI-RADSv2.1 category 3, category 3h, category 4, and category 4h. The clinical utility of each model was measured as the net benefit at 10%, 20%, 30%, and 40% risk probability of csPCa, and was plotted over the 0–99% range of risk probability in order to build decision analysis curves. The net benefit expresses the percent gain in true-positives adjusted for false-positive results, given a certain threshold probability of harboring csPCa.23,24 The decision analysis was repeated for each PSAD reference level.

All analyses were performed with commercially available software (MedCalc Software v.19.8 Ltd, Stata Statistical Software, v.17). Decision analysis was run on Stata using source codes freely available at https://www.mskcc.org/departments/epidemiology-biostatistics/biostatistics/decision-curve-analysis. The standard of reference for ROC analysis and decision analysis was the combination of targeted plus systematic biopsy.

RESULTS

Median patient age, serum PSA level and PSAD value were 67.0 years (IQR 67.0–72.5), 6.16 ng ml⁻¹ (IQR 6.1–9.3) and 0.12 ng/ml ml⁻¹ (IQR 0.12–0.17), respectively.

R1 and R2 evaluated 82/123 (66.7%) and 41/123 (33.3%) examinations, respectively. Index lesions were categorized as PI-RADSv2.1 category 1 in 18 cases (14.6%), category 2 in 12 cases (9.7%), category 3 in 11 cases (8.9%), category 4 in 47 cases (38.2%), and category 5 in 35 cases (28.4%). Of the 123 men, those with category ≥3 index lesions (75.6%) underwent targeted biopsy plus systematic biopsy, while the remaining 30 men with negative mpMRI underwent systematic biopsy only. csPCa was found in 54/123 men (43.9%; 95% CI 40.5–70.4), with 27/54 ISUP 2 cancers (50.0%), 17/54 ISUP 3 cancers (31.5%), 6/54 ISUP 4 cancers (11.1%), and 4/54 ISUP 5 cancers (7.4%). Thirteen other men (10.5%; 95% CI 6.9–22.2) were diagnosed with ISUP 1 cancers. Of men referred to biopsy, 14 also showed 14 non-index suspicious lesions [category 3 in four cases (28.5%), and category 4 in 10 cases (71.4%)], all of which underwent additional targeted biopsy with a final diagnosis of csPCa in 10/14 cases (71.4%). Positivity of the non-index lesions was associated with true-positive index lesions in all cases. Details on CDR are shown in Table 1. Nine out of 47 category 4 assignments were upgraded from the initial category 3. Three out of nine cases were true-positive ISUP 2 cancers with PSAD ≥0.10 ng/ml ml⁻¹, while the remaining six cases were false-positives (PSAD ≤0.10 and >0.10 ng/ml ml⁻¹ in 3 and 3 cases, respectively).

Diagnostic accuracy of PI-RADSv2.1 categories adjusted or not for PSAD

On ROC analysis, PI-RADSv2.1 categorization achieved 92.6% sensitivity (95% CI 82.1–97.7%) and 53.6% specificity (95% CI 41.2–65.7%) for a category ≥3 threshold, corresponding to an AUC of 0.82 (95% CI 0.74–0.88). Sensitivity, specificity, and AUC for PSAD-adjusted categorization were 85.2% (95% CI 72.9–93.4%), 72.5% (95% CI 60.4–82.5%), and 0.84 (95% CI 0.77–0.90) at ≥0.10 ng/ml ml⁻¹, and 62.9% (95% CI 48.7–75.7%), 85.5% (95% CI 75.0–92.8%), and 0.83 (95% CI 0.75–0.89) at ≥0.15 ng/ml ml⁻¹ (Supplementary Figure 2). At both PSAD levels, the Youden index corresponded to a PI-RADSv2.1 ≥4h cut-off. In the case of ≥0.20 ng/ml ml⁻¹ threshold, 92.6% sensitivity (95% CI 81.8–97.9%), 53.6% specificity (95% CI 41.2–65.7%), and 0.82 AUC (95% CI 0.74–0.88%) were achieved for a PI-RADSv2.1 ≥4 cut-off. Sensitivity and specificity obtained at each PSAD threshold
Table 1. Cancer detection rate for clinically significant prostate cancer on a per Prostate Imaging – Reporting And Data System v.2.1 basis with and without stratification by PSA density

| PI-RADSv2.1 category of index lesion (N.patients) | PSAD threshold (ng/ml ml⁻¹) | PSAD value (ng/ml ml⁻¹) (N.patients) | CDR for csPCa on targeted biopsy (%) | CDR for csPCa on target + systematic biopsy (%) | Number of false-positives on targeted biopsy (%) |
|-----------------------------------------------|-----------------------------|--------------------------------------|-------------------------------------|-------------------------------------------------|---------------------------------|
| ≤2 (30)                                       | 0.10                        | Any (30)                             | NA                                  | 2/30 (6.7)                                       | NA                              |
|                                              |                             | <0.10 (16/30)                        | NA                                  | 1/16 (6.2)                                       | NA                              |
|                                              |                             | ≥0.10 (14/30)                        | NA                                  | 1/14 (7.1)                                       | NA                              |
|                                              | 0.15                        | Any (30)                             | NA                                  | 2/30 (6.7)                                       | NA                              |
|                                              |                             | <0.15 (26/30)                        | NA                                  | 1/26 (3.8)                                       | NA                              |
|                                              |                             | ≥0.15 (4/30)                         | NA                                  | 1/4 (25.0)                                       | NA                              |
|                                              | 0.20                        | Any (30)                             | NA                                  | 2/30 (6.7)                                       | NA                              |
|                                              |                             | <0.20 (27/20)                        | NA                                  | 2/27 (7.4)                                       | NA                              |
|                                              | 3 (11)                      | 0.10                                 | Any (11)                            | 2/11 (18.1)                                      | 9/11 (81.8)                     |
|                                              |                             | <0.10 (6/11)                         | 2/6 (33.3)                          | 4/6 (66.7)                                       | 5/100 (50%)                     |
|                                              |                             | ≥0.10 (5/11)                         | 0/5 (0.0)                           | 0/5 (0.0)                                        | 5/100 (100%)                   |
|                                              |                             | 0.15                                 | Any (11)                            | 2/11 (18.2)                                      | 9/11 (81.8)                     |
|                                              |                             | <0.15 (10/11)                        | 2/10 (20.0)                         | 8/10 (80.0)                                      | 1/1 (100.0)                    |
|                                              |                             | ≥0.15 (1/11)                         | 0/1 (0.0)                           | 0/1 (0.0)                                        | 1/1 (100.0)                    |
|                                              |                             | 0.20                                 | Any (11)                            | 2/11 (18.2)                                      | 9/11 (81.8)                     |
|                                              |                             | <0.20 (10/11)                        | 2/10 (20.0)                         | 8/10 (80.0)                                      | 1/1 (100.0)                    |
|                                              |                             | ≥0.20 (1/11)                         | 0/1 (0.0)                           | 0/1 (0.0)                                        | 1/1 (100.0)                    |
|                                              | 4 (47)                      | 0.10                                 | Any (47)                            | 20/47 (42.5)                                     | 21/47 (44.7)                   |
|                                              |                             | <0.10 (17/47)                        | 4/17 (23.5)                         | 4/17 (23.5)                                      | 13/17 (76.5)                   |
|                                              |                             | ≥0.10 (30/47)                        | 16/30 (53.3)                        | 17/30 (56.7)                                     | 14/30 (46.7)                   |
|                                              |                             | 0.15                                 | Any (47)                            | 20/47 (42.5)                                     | 21/47 (44.6)                   |
|                                              |                             | <0.15 (38/47)                        | 15/38 (39.4)                        | 16/38 (42.1)                                     | 23/38 (60.6)                   |
|                                              |                             | ≥0.15 (9/47)                         | 5/9 (55.5)                          | 5/9 (55.5)                                       | 4/9 (44.5)                     |
|                                              |                             | 0.20                                 | Any (47)                            | 20/47 (42.5)                                     | 21/47 (44.6)                   |
|                                              |                             | <0.20 (43/47)                        | 19/43 (44.1)                        | 20/43 (46.5)                                     | 24/43 (55.9)                   |
|                                              |                             | ≥0.20 (4/47)                         | 1/4 (25.0)                          | 1/4 (25.0)                                       | 3/4 (75.0)                     |
|                                              | 5 (35)                      | 0.10                                 | Any (35)                            | 29/35 (82.8)                                     | 29/35 (82.8)                   |
|                                              |                             | <0.10 (5/35)                         | 3/5 (60.0)                          | 3/5 (60.0)                                       | 2/5 (40.0)                     |
|                                              |                             | ≥0.10 (30/35)                        | 26/30 (86.6)                        | 26/30 (86.6)                                     | 4/30 (13.4)                    |
|                                              |                             | 0.15                                 | Any (35)                            | 29/35 (82.8)                                     | 29/35 (82.8)                   |
|                                              |                             | <0.15 (10/35)                        | 8/10 (80.0)                         | 8/10 (80.0)                                       | 2/10 (20.0)                    |
|                                              |                             | ≥0.15 (25/35)                        | 21/25 (84.0)                        | 21/25 (84.0)                                     | 4/25 (16.0)                    |
|                                              |                             | 0.20                                 | Any (35)                            | 29/35 (82.8)                                     | 29/35 (82.8)                   |
|                                              |                             | <0.20 (15/35)                        | 11/15 (73.3)                        | 11/15 (73.3)                                     | 4/15 (26.7)                    |
|                                              |                             | ≥0.20 (20/35)                        | 18/20 (90.0)                        | 18/20 (90.0)                                     | 2/20 (10.0)                    |

CDR, Cancer detection rate; NA, Not applicable; PI-RADSv2.1, Prostate imaging–reporting and data system version 2.1; PSAD, PSA density; csPCa, Clinically significant prostate cancer.
Pairwise comparison between AUCs showed significant difference between PSAD ≥0.10 ng/ml ml⁻¹ versus ≥0.20 ng/ml ml⁻¹-adjusted categorization (p = 0.041). Other comparisons were not significant (p = 0.115 for PSAD values ≥0.10 versus ≥0.15 ng/ml ml⁻¹, and p = 0.376 for ≥0.15 versus ≥0.20 ng/ml ml⁻¹).

Decision analysis
When comparing the net benefit of different PI-RADS thresholds triggering biopsy, we obtained decision analysis curves as shown in Figure 3. Absolute net benefit values at different PSAD-adjusted levels are reported in Table 2. PI-RADS 4h category adjusted for PSAD ≥0.10 ng/ml ml⁻¹ was the biopsy trigger with the greatest net benefit for risk probabilities corresponding to the expected prevalence of csPCa in unselected biopsy-naïve patients. Table 3 provides an overview of false-positive and false-negative cases using unadjusted and PSAD-adjusted PI-RADSv2.1 categories. Regardless of the PSAD threshold used, most false-negatives were ISUP 2 cancers.

DISCUSSION
We observed that the adjustment of PI-RADSv2.1 categories for a PSAD threshold ≥0.10 ng/ml ml⁻¹ achieved higher AUC for csPCa than other values (≥0.15 and ≥0.20 ng/ml ml⁻¹) and unadjusted PI-RADSv2.1 categorization. The latter showed unbalanced high sensitivity and low specificity, in line with a recent meta-analysis on PI-RADSv2.1 accuracy (94 and 56% pooled sensitivity and specificity for a category ≥3 cut-off, respectively). Combining category 4h and PSAD ≥0.10 ng/ml ml⁻¹ as a trigger for biopsy was the strategy with the highest net benefit on decision analysis when the probability of csPCa was assumed to be 30 and 40%, that is, within the expected range of csPCa prevalence (28–49%, average 39%) in unselected biopsy-naïve patients.

Figure 1. True-positive PI-RADS 4 index lesion with high PSAD (0.33 ng/ml ml⁻¹) in a 61-year-old male with an International Society of Urogenital Pathology (ISUP) grading group 2 cancer on targeted biopsy. On multiparametric magnetic resonance imaging (mpMRI), the index lesion appeared as a 12 mm focal zone of restricted diffusion in the lateral posterior peripheral zone of the right base, with hyperintensity on the b = 2000 sec/mm² image (arrow in a), and hypointensity on the apparent diffusion coefficient (ADC) map (arrow in b). This finding also showed moderate hypointensity on corresponding axial T2-weighted image (arrow in c), and focal enhancement on subtracted dynamic contrast-enhanced imaging (arrow in d).

Figure 2. False-positive PI-RADS four index lesion in a 64-year-old patient with low PSAD (0.09) ng/ml ml⁻¹ and negative-targeted and systematic biopsy. mpMRI showed a 5 mm focus of restricted diffusion in the lateral posterior peripheral zone of the right mid-gland, appearing as an hyperintense focus on high b-value image (arrow in a), and tiny focal hypointensity on the ADC map (arrow in b) corresponding to mild hypointensity on axial T2-weighted imaging (arrow in c) and focal contrast-enhancement on dynamic contrast-enhanced imaging (arrow in d). Of note, the lesion was no longer visible on the same sequences (e–h) of a subsequent mpMRI performed 6 months after the biopsy. On this basis, the lesion was retrospectively assessed as focal prostatitis.
biopsy-naïve patients. This was not the case for strategies adjusting for PSAD of 0.15 and 0.20 ng/ml ml⁻¹, for which category 3h or four showed comparable net benefit.

Similarly to a study by Falagario et al with a comparable csPCa prevalence (40.19%) and median PSAD (0.13 ng/ml ml⁻¹), we confirmed the added value of PSAD in stratifying csPCa risk. However, in that study, the authors found greater clinical utility of different strategies with or without PSA adjustment, or with different PSAD thresholds, namely biopsyng PI-RADSv2.1/Likert category ≥4 lesions and/or PI-RADSv2.1/Likert category ≥3 lesions if PSAD >0.20 ng/ml ml⁻¹ (main strategy), or PI-RADSv2.1/Likert ≥4 findings and/or PI-RADSv2.1/Likert ≥4 findings if PSAD >0.10 and/or >0.20 ng/ml ml⁻¹ (secondary strategy). While obtained on a small study population, our findings suggest a more definite approach combining more uniform interpretation criteria (PI-RADSv2.1) with a lower PSAD threshold.

In our series, the adjustment for PSAD reduced false-positive assignments, as witnessed by increased PPV of adjusted

Table 2. Decision analysis showing the expected benefit of performing biopsy using the reported Prostate Imaging – Reporting And Data System v.2.1 categories for 10–40% threshold probabilities

| PSAD threshold (ng/ml ml⁻¹) | Risk probability | Net benefit according to the PI-RADSv2.1 cutoff |
|-----------------------------|-----------------|---------------------------------------------|
|                             | 3   | 3h  | 4    | 4h   | Treat all |
| 0.10                        |     |     |      |      |            |
| 10%                         | 0.385 | 0.373 | 0.377 | 0.356 | 0.376 |
| 20%                         | 0.339 | 0.331 | 0.341 | 0.335 | 0.298 |
| 40%                         | 0.200 | 0.206 | 0.233 | 0.271 | 0.065 |
| 0.15                        |     |     |      |      |            |
| 10%                         | 0.385 | 0.376 | 0.376 | 0.266 | 0.376 |
| 20%                         | 0.339 | 0.339 | 0.339 | 0.254 | 0.298 |
| 40%                         | 0.200 | 0.227 | 0.227 | 0.216 | 0.065 |
| 0.20                        |     |     |      |      |            |
| 10%                         | 0.385 | 0.376 | 0.377 | 0.243 | 0.376 |
| 20%                         | 0.339 | 0.339 | 0.341 | 0.233 | 0.298 |
| 40%                         | 0.200 | 0.227 | 0.233 | 0.203 | 0.065 |

PSAD, prostate specific antigen density; 3h, PI-RADSv2.1 category three with PSAD above the established threshold; 4h, PI-RADSv2.1 category four with PSAD above the established threshold.

“Treat all” is assumed to represent the strategy of performing prostate biopsy to all patients.
| PSAD (ng/ml ml⁻¹) | PI-RADSv2.1 cut-off | PPV% (95% CI) | NPV% (95% CI) | TP patients (N) | TN patients (N) | FP patients (N) | FN patients (N) |
|------------------|---------------------|----------------|----------------|----------------|----------------|----------------|----------------|
|                  |                     |                |                |                |                |                | ISUP ≥2 | ISUP 2 | ISUP 3 | ISUP 4 | ISUP 5 |
| 0.10             | 3                   | 55.9 (41.7–73.3) | 93.3 (62.0–100) | 52             | 28             | 41             | 2 | 0 | 2 | 0 | 0 |
|                  | 3h                  | 58.1 (43.1–76.6) | 89.2 (61.4–100) | 50             | 33             | 36             | 4 | 2 | 2 | 0 | 0 |
|                  | 4                   | 61.0 (45.2–80.4) | 90.2 (63.5–100) | 50             | 37             | 32             | 4 | 2 | 2 | 0 | 0 |
|                  | 4h                  | 70.8 (51.8–94.4) | 86.2 (63.9–100) | 46             | 50             | 19             | 8 | 4 | 4 | 0 | 0 |
| 0.15             | 3                   | 55.9 (41.7–73.3) | 93.3 (62.0–100) | 52             | 28             | 41             | 2 | 0 | 2 | 0 | 0 |
|                  | 3h                  | 60.2 (44.7–79.4) | 90.0 (63.0–100) | 50             | 36             | 33             | 4 | 2 | 2 | 0 | 0 |
|                  | 4                   | 61.0 (45.2–80.4) | 90.2 (63.5–100) | 50             | 37             | 32             | 4 | 2 | 2 | 0 | 0 |
|                  | 4h                  | 77.3 (53.5–100)  | 74.7 (56.8–96.3) | 34             | 59             | 10             | 20 | 12 | 6 | 2 | 0 |
| 0.20             | 3                   | 55.9 (41.7–73.3) | 93.3 (62.0–100) | 52             | 28             | 41             | 2 | 0 | 2 | 0 | 0 |
|                  | 3h                  | 60.2 (44.7–79.4) | 90.0 (63.0–100) | 50             | 36             | 33             | 4 | 2 | 2 | 0 | 0 |
|                  | 4                   | 61.0 (45.2–80.4) | 90.2 (63.5–100) | 50             | 37             | 32             | 4 | 2 | 2 | 0 | 0 |
|                  | 4h                  | 76.9 (51.9–100)  | 71.4 (54.5–91.9) | 30             | 60             | 9              | 24 | 15 | 6 | 3 | 0 |

FN, False negative; FP, False positive; ISUP, International Society of Urogenital Pathology; NPV, Negative predictive value; PI-RADSv2.1, Prostate imaging – reporting and data system version 2.1; PPV, Positive predictive value; PSAD, PSA density; TN, True negative; TP, True positive; 3h, PI-RADSv2.1 category three with PSAD above the established threshold; 4h, PI-RADSv2.1 category four with PSAD above the established threshold.

International Society of Urogenital Pathology grading group are provided for false-negative cancers.
PI-RADSv2.1 categories potentially triggering biopsy (3h and 4h) compared to unadjusted categories (3 and 4). CDR increased, too, with a higher prevalence of cancers in category 4 assignments associated with high PSAD than those with low PSAD, regardless of the PSAD threshold used. While the overall trend for category 4 and 5 lesions as a whole is in line with previous reports,\textsuperscript{9,25–29} the stratified analysis showed that the gain from PSAD-adjustment was low for category 5, as the per-category CDR increased only slightly, that is, from 82.8% to 84.0–90.0% depending on the PSAD threshold used. This was an expected result, given the high risk for csPca inherent to PI-RADSv2.1 5 lesions, for which CDR has been reported 72–73% in previous studies.\textsuperscript{13,30}

On the contrary, the CDR for the unadjusted category four was relatively low (42.5%). This value compares to the CDR shown in systematic reviews by Barkovich et al\textsuperscript{13} (48.0%) and Schoots\textsuperscript{30} (39.0% for ISUP ≥2 cancers), suggesting that PI-RADS 4 assignments are a frequent false-positive source of unnecessary biopsy. While we were not able to identify clinical and mpMRI-related features associated with false-positive category 4 assignments, we showed that category 4 was the one benefiting the most from PSAD-adjustment, with CDR increasing from 42.5–44.6% to 55.5–56.6% when using ≥0.10–0.15 ng/mL ml\textsuperscript{−1} thresholds. This effect was not found for a PSAD ≥0.20 ng/mL ml\textsuperscript{−1}, possibly because only a few men with category 4 index lesions showed a PSA level above that threshold (n = 4). Of note, PSAD-adjustment did not affect the CDR of category 3 lesions. This might be explained by the low number of category 3 assignments in our series, accounting for 11/123 (8.9%) index observations. As PI-RADS three lesions are expected to be comparably low (<10%) in a high volume center,\textsuperscript{9} our results corroborate the concept that in this ideal scenario the main target to minimize false-positives might be PI-RADS 4 category.

After pooling different studies using PSAD to stratify PI-RADS categories, Schoots et al\textsuperscript{10} showed that 31% of men with high-risk mpMRI findings (PI-RADS 4–5 observations) are expected to harbor csPca despite low PSAD (<0.10 ng/mL ml\textsuperscript{−1}). This would be the base for recommending biopsy in categories 4–5 regardless of PSAD. Our results are difficult to compare, as we did not merge the two categories. Using a PSAD ≥0.10 ng/mL ml\textsuperscript{−1} and PI-RADS 4h as a potential cut-off for triggering biopsy, we showed an NPV (86.2%) approaching the value expected for category 3 as the trigger for biopsy (90.8%).\textsuperscript{31} This combination corresponded to a lower proportion of false-negative csPca cases compared to stratifying category 4 for higher PSAD values, and to a 70.7% PPV, which is significantly higher than the 40% pooled PPV recently reported in the meta-analysis by Mazzone et al\textsuperscript{32}. Our results should be interpreted with caution, given the need for validation in larger prospective series. However, we believe they might represent a basis for further research, especially regarding how the risk inherent to each PI-RADS-adjusted category may impact on the decision to biopsy.

We acknowledge some limitations to our study. First, our study population is relatively small and has been collected on a monocentric basis. Further prospective studies on larger series should be performed to validate our findings. Second, the retrospective use of clinical mpMRI readings for the analysis implied unblinding to PSAD. One might argue that the knowledge of PSAD might have influenced mpMRI readings, for example by inducing the radiologist to consider a finding as more focal and/or conspicuous on DWI in the case of higher PSAD. We believe that similar potential effects on image analysis were reasonably limited by the fact that PSAD has no impact on the PI-RADS decision rules.\textsuperscript{19} However, our results might be of limited generalizability in a setting in which image analysis is performed with the Likert assessment, which can be influenced by prior knowledge of PSAD.\textsuperscript{19} Second, we estimated the prostate gland volume for calculating PSAD according to the PI-RADSv2.1 rules.\textsuperscript{19} Using volumetric segmentation as the standard of reference, Ghafoor et al\textsuperscript{14} found that our method slightly overestimated the prostate volume compared to the PI-RADSv2.0 method.\textsuperscript{35} While differences were minimal in absolute terms, the PI-RADSv2.0 method was advocated as a more reliable tool to calculate PSAD. Another study on 397 patients\textsuperscript{26} showed that the PI-RADS v2.1-derived volume did not affect the accuracy of PSAD for ISUP ≥2 cancers compared to the segmentation-derived volume, although the accuracy for ISUP ≥4 cancers was greater when PSAD was calculated with the latter method. Overall, although our findings are reasonably generalizable in a PI-RADS v.2.1-centered context, they should be confirmed in a setting using segmentation-derived volumes as the surrogate standard of reference.\textsuperscript{37} Third, our results were obtained on a per-patient rather than per-lesion basis, thus possibly overemphasizing the sensitivity and PPV. On the other hand, we observed 14 suspicious non-index lesions, all of which underwent additional targeted biopsy with a final diagnosis of csPca in most cases. This suggests that sensitivity inflation, if any, would be reasonably limited. Finally, we used full mpMRI, thus making the results not generalizable to the setting of biparametric MRI, for which ad hoc studies should be performed.

**CONCLUSIONS**

Our study showed that PSAD ≥0.10 ng/mL ml\textsuperscript{−1} was the threshold with the greatest clinical utility in stratifying PI-RADSv2.1 categories for csPca. This threshold corresponded to higher AUC and better balance between sensitivity and specificity than PSAD ≥0.15 or ≥0.20 ng/mL ml\textsuperscript{−1}. On decision analysis, PI-RADSv2.1 category 4 adjusted for PSAD ≥0.10 ng/mL ml\textsuperscript{−1} was the biopsy trigger with the greatest net benefit for risk probabilities corresponding to the expected prevalence of csPca in unscreened biopsy-naïve men. If confirmed in larger prospective studies, our results might emphasize the concept that the combination of lower PSAD threshold and higher PI-RADSv2.1 cut-off may allow better risk stratification for referral to prostate biopsy.

**COMPETING INTERESTS**

The Authors have no competing interests to disclose.

**FUNDING**

Open Access Funding provided by Universita degli Studi di Udine within the CRUI-CARE Agreement.

**PATIENT CONSENT**

Waived by the IRB because of the retrospective design, and use of anonymized data.
REFERENCES

1. Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaalar MH, et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med 2018; 378: 1767–77. doi: https://doi.org/10.1056/NEJMoa1819993

2. Boesen L, Nørgaard N, Logager V, Balslev J, Bisbjerg R, Thestrup K-C, et al. Assessment of the diagnostic accuracy of biparametric magnetic resonance imaging for prostate cancer in biopsy-naïve men. JAMA Netw Open 2018; 1: e180219; e180219-. doi: https://doi.org/10.1001/jamanetworkopen.2018.0219

3. van der Leest M, Cornel E, Israel B, Hendriks R, Padhani AR, Hoogenboom M, et al. Head-To-Head comparison of transrectal ultrasound-guided prostate biopsy versus multiparametric prostate biopsy imaging with subsequent magnetic resonance-guided biopsy in biopsy-naïve men with elevated prostate-specific antigen: a large prospective multicenter clinical study. Eur Urol 2019; 75: 570–8. doi: https://doi.org/10.1016/j.eururo.2018.11.023

4. Rouvière O, Puech P, Renard-Penna R, Puech P, Villeirs G, Macura KJ, Margolis DJA, et al. PI-RADS Committee position on MRI without contrast medium in biopsy-naïve men with suspected prostate cancer: narrative review. American Journal of Roentgenology 2021; 216: 3–19. doi: https://doi.org/10.2214/AJR.20.24268

5. Jambor I, Verho J, Ettala O, Knaapila J, Taimen P, Syvänen KT, et al. Validation of IMPROD biparametric MRI in men with clinically suspected prostate cancer: a prospective multi-institutional study. J Urol 2019; 201: 100–9. doi: https://doi.org/10.1016/j.juro.2018.08.046

6. Schoots IG, Padhani AR, Hoogen boom M, et al. Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naïve patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study. Lancet Oncol 2019; 20: 100–9. doi: https://doi.org/10.1016/S1470-2247(18)30569-2

7. Padhani AR, Barentsz JO, Bittencourt LK, Haider MA, Macura KJ, Margolis DJA, et al. PI-RADS Committee position on MRI without contrast medium in biopsy-naïve men with suspected prostate cancer: narrative review. American Journal of Roentgenology 2021; 216: 3–19. doi: https://doi.org/10.2214/AJR.20.24268

8. Oishi M, Shin T, Ohe C, Nassisti N, Palmer SL, Aron M, et al. Which patients with negative magnetic resonance imaging can safely avoid biopsy for prostate cancer? J Urol 2019; 201: 268–77. doi: https://doi.org/10.1016/j.juro.2018.08.046

9. Tan N, Lin W-C, Khoshnoodi P, Asvadi NH, Yoshida J, Margolis DJA, et al. In-Bore 3-T MR-guided transrectal targeted prostate biopsy: prostate imaging reporting and data system version 2-based diagnostic performance for detection of prostate cancer. Radiology 2017; 283: 130–9. doi: https://doi.org/10.1148/radiol.2016152827

10. Barkovich EJ, Shankar PR, Westphalen AC. A systematic review of the existing prostate imaging reporting and data system version 2 (PI-RADSV2) literature and subset meta-analysis of PI-RADsV2 categories stratified by Gleason scores. AJR Am J Roentgenol 2019; 212: 847–54. doi: https://doi.org/10.2214/AJR.18.20571

11. Stevens E, Truong M, Bullen JA, Ward RD, Puryasko AS, Klein EA. Clinical utility of PsaD combined with PI-RADS category 4 for the detection of clinically significant prostate cancer. Urol Oncol 2020; 38: 846.e9–846.e16. doi: https://doi.org/10.1016/j.urolonc.2020.05.024

12. Purysko AS, Bell'un J, Valdez R, Auschof E, D’Ippolito G, Klein EA. Influence of 5-alpha reductase inhibitors on prostate cancer detection with magnetic resonance imaging: a matched cohort study. J Urol 2021; 6: 101097/UROLOGY0000000001932. doi: https://doi.org/10.1097/JU.0000000000001932

13. Epstein JI, Egevad L, Amin MB, Delahunt B, Padhani AR, Velleirs G, et al. PI-RADS Committee position on MRI without contrast medium in biopsy-naïve men with suspected prostate cancer: narrative review. American Journal of Roentgenology 2021; 216: 3–19. doi: https://doi.org/10.2214/AJR.20.24268

14. Debruyne F, Barkin J, Erps P, Reis M, Tammela T, Roehrborn C, van Erps P. Efficacy and safety of long-term treatment with the dual 5α-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol 2004; 46: 488–95. doi: https://doi.org/10.1016/j.eururo.2004.05.008

15. Wadera A, Alabousi M, Pozdnyakov A, Kashif Al-Ghita M, Jafari A, Mclnnes MD, et al. Impact of PI-RADS category 3 lesions on the diagnostic accuracy of MRI for detecting prostate cancer and the prevalence of prostate cancer within each PI-RADS category: a systematic review and meta-analysis. Br J Radiol 2021; 94: 20191050. doi: https://doi.org/10.1259/bjr.20191050

16. Giganti F, Moore CM, Robertson NL, McCrattan N, Jameson C, B0tt SRI, et al. MRI findings in men on active surveillance for prostate cancer: does dutasteride make MRI visible lesions less conspicuous? results from a placebo-controlled, randomised clinical trial. Eur Radiol 2017; 27: 4767–74. doi: https://doi.org/10.1007/s00330-017-4858-0

17. Purysko AS, Bell'un J, Valdez R, Auschof E, D’Ippolito G, Klein EA. Influence of 5-alpha reductase inhibitors on prostate cancer detection with magnetic resonance imaging: a matched cohort study. J Urol 2021; 6: 101097/UROLOGY0000000001932. doi: https://doi.org/10.1097/JU.0000000000001932

18. Debruyne F, Barkin J, Erps P, Reis M, Tammela T, Roehrborn C, van Erps P. Efficacy and safety of long-term treatment with the dual 5α-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol 2004; 46: 488–95. doi: https://doi.org/10.1016/j.eururo.2004.05.008

19. Turkbey B, Rosenkrantz AB, Haider MA, Padhani AR, Velleirs G, Macura KJ, et al. Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2. Eur Urol 2019; 76: 340–51. doi: https://doi.org/10.1016/j.eururo.2019.02.033

20. Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA, et al. The 2014 International Society of urological pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol 2016; 40: 244–52. doi: https://doi.org/10.1097/PAS.0000000000005030
21. Smits N. A note on Youden’s J and its cost ratio. *BMC Med Res Methodol* 2010; 10: 89. doi: https://doi.org/10.1186/1471-2288-10-89

22. Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. *Med Decis Making* 2006; 26: 565–74. doi: https://doi.org/10.1177/0272989X06295361

23. Vickers AJ, Van Calster B, Steyerberg EW. Net benefit approaches to the evaluation of prediction models, molecular markers, and diagnostic tests. *BMJ* 2016; 352: i6. doi: https://doi.org/10.1136/bmj.i6

24. Steyerberg EW, Vickers AJ, Cook NR, Gerds T, Goen M, Obuchowski N, et al. Assessing the performance of prediction models: a framework for traditional and novel measures. *Epidemiology* 2010; 21: 128–38. doi: https://doi.org/10.1097/EDE.0b013e3181c30fb2

25. Park KJ, Choi SH, Kim M-H, Kim JK, Jeong IG. Performance of prostate imaging reporting and data system version 2.1 for diagnosis of prostate cancer: a systematic review and meta-analysis. *J Magn Reson Imaging* 2021; 54: 103–12. doi: https://doi.org/10.1002/jmri.27546

26. Boesen L, Nørgaard N, Løgager V, Balslev I, Bisbjerg R, Thestrup K-C, et al. Prebiopsy IMPROD: biparametric magnetic resonance imaging combined with prostate-specific antigen density in the diagnosis of prostate cancer: an external validation study. *Eur Urol Oncol* 2020; 3: 648–56. doi: https://doi.org/10.1016/j.euro.2019.08.008

27. Falagario UG, Martini A, Wajswol E, Treacy P-J, Ratnani P, Jambor I, et al. Avoiding unnecessary magnetic resonance imaging (MRI) and biopsies: negative and positive predictive value of MRI according to prostate-specific antigen density, 4Kscore and risk calculators. *Eur Urol Oncol* 2020; 3: 700–4. doi: https://doi.org/10.1016/j.euro.2019.08.015

28. Knaapila J, Jambor I, Perez IM, Ettala O, Taimen P, Verho J, et al. Prebiopsy IMPROD: biparametric magnetic resonance imaging combined with prostate-specific antigen density in the diagnosis of prostate cancer. *BJU Int* 2018; 122: 40–9. doi: https://doi.org/10.1111/bju.14049

29. Hansen NL, Barrett T, Kesch C, Pepdjonovic L, Bonekamp D, O’Sullivan R, et al. Multicentre evaluation of magnetic resonance imaging supported transperineal prostate biopsy in biopsy-naive men with suspicion of prostate cancer. *BJU Int* 2018; 122: 565–74. doi: https://doi.org/10.1111/bju.12893

30. Schoots IG. MRI in early prostate cancer detection: how to manage indeterminate or equivocal PI-RADS 3 lesions? *Transl Androl Urol* 2018; 7: 70–82. doi: https://doi.org/10.2214/AJR.17.60772

31. Sathianathen NJ, Omer A, Harriss E, Davies L, Kasivisvanathan V, Punwani S, et al. Negative predictive value of multiparametric magnetic resonance imaging in the detection of clinically significant prostate cancer in the prostate imaging reporting and data system era: a systematic review and meta-analysis. *Eur Urol* 2020; 78: 402–14. doi: https://doi.org/10.1016/j.euro.2020.03.048

32. Mazzone E, Stabile A, Pellegrino F, Basile G, Cignoli D, Cirulli GO, et al. Positive predictive value of prostate imaging reporting and data system version 2 for the detection of clinically significant prostate cancer: a systematic review and meta-analysis. *Eur Urol Oncol* 2020; 25: 30212–1. doi: https://doi.org/10.1016/j.euro.2020.12.004

33. Latifoltojar A, Appayya MB, Barrett T, Punvani S. Similarities and differences between Likert and PIRADS v2.1 scores of prostate multiparametric MRI: a pictorial review of histology-validated cases. *Clin Radiol* 2019; 74: 895.e1–895.e15. doi: https://doi.org/10.1016/j.crad.2019.08.020

34. Ghafoor S, Becker AS, Woo S, Causa Andrieu PI, Stocker D, Gangai N, et al. Comparison of PI-RADS versions 2.0 and 2.1 for MRI-based calculation of the prostate volume. *Acad Radiol* 2020; 4. doi: https://doi.org/10.1016/j.acra.2020.07.027

35. Weinreb JC, Barentsz JO, Choyke PL, Cornud F, Haider MA, Macura KJ, et al. PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2. *Eur Urol* 2016; 69: 16–40. doi: https://doi.org/10.1016/j.euro.2015.08.052

36. Colvin R, Walker D, Hafron J, Seifman B, Nandalur S, Gangwish D, et al. Which measurement method should be used for prostate volume for PI-RADS? A comparison of ellipsoid and segmentation methods. *Clin Imaging* 2021; 80: 454–8. doi: https://doi.org/10.1016/j.clinimag.2021.09.003

37. Turkbey B, Fotin SV, Huang RJ, Yin Y, Daar D, Aras O, et al. Fully automated prostate segmentation on MRI: comparison with manual segmentation methods and specimen volumes. *AJR Am J Roentgenol* 2013; 201: W720–9. doi: https://doi.org/10.2214/AJR.12.9712